Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02856646 · ClinicalTrials.gov registry record
Hodgkin Lymphoma Molecular Profiling and Clinical Outcomes in U.S. Community Oncology Practices
A clinical trial, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- 290
- Enrollment target
NCT02856646: Completed study, sponsored by Bristol-Myers Squibb.
NCT02856646 is a clinical trial that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 290 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02856646 has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- 290 participants
- Enrollment target
Study Summary
The purpose of this study is to gather data on patients diagnosed with and treated for classical Hodgkin Lymphoma (cHL). It aims to closely observe how treatment for cHL is rendered, as well as assess the outcome of those treatment options and their impact on quality of life. Additional analyses will also attempt to identify prognostic or predictive biomarkers
Primary Outcome
What are the treatment patterns of therapies used to treat cHL (ie, incorporation of novel chemotherapy or non-chemotherapy to upfront therapy, chemotherapy/radiation and/or transplant sparring patterns, incorporation of immune checkpoint agents or other investigational therapies)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 290 participants |
| Start Date | 2016-10-07 |
| Est. Completion | 2020-09-30 |
What the finished NCT02856646 record still lists
NCT02856646 is an observational study that tracks outcomes without assigning an intervention. The registered 290 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT02856646 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02856646 about?
NCT02856646 is a clinical study titled "Hodgkin Lymphoma Molecular Profiling and Clinical Outcomes in U.S. Community Oncology Practices". The purpose of this study is to gather data on patients diagnosed with and treated for classical Hodgkin Lymphoma (cHL). It aims to closely observe how treatment for cHL is rendered, as well as assess the outcome of those treatment options and their impact on quality of life. Additional analyses wil...
What is the current status of trial NCT02856646?
This trial is currently completed. The enrollment target is 290 participants. The study started on 2016-10-07. Estimated completion is 2020-09-30.
Who is sponsoring clinical trial NCT02856646?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00775476 · 290 participants · Phase 2
Treatment of Systemic Lupus Erythematosus (SLE) With N-acetylcysteine
- NCT01874197 · 290 participants · NA
Branched Thoracic Endovascular Grafts for the Treatment of Thoraco-abdominal Aortic
- NCT04331353 · 290 participants · NA
The Allergen Reduction and Child Health Study (ARCHS)
- NCT04649008 · 290 participants · Early Phase 1
Localizing Epileptic Networks Using MRI and iEEG
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI